Axcan Pharma News
Most Popular Axcan Pharma Story
Axcan to buy Eurand for $583 million
Axcan Holdings has struck a deal to buy Eurand for $583 million. Shareholders are in line for $12 a share, a meager 9.4 percent premium over yesterday's close. "The last several years have seen Read more...
Latest Headlines
- November 9, 2011
- December 1, 2010
- November 29, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
